Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma

Molecular Cancer Research

Volumn 10, Issue 2, 2012, Pages 208-217

  Lin, Ningjing ^a   Di, Chunhui ^b   Bortoff, Kathy ^b   Fu, Jinrong ^b   Truszkowski, Peter ^b   Killela, Patrick ^b   Duncan, Chris ^b   McLendon, Roger ^b   Bigner, Darell ^b   Gregory, Simon ^b   Adamson, David Cory ^b,c  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHERENS JUNCTIONAL ASSOCIATED PROTEIN 1; GENOMIC DNA; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 1P; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETIC SILENCING; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE MAPPING; GENE SILENCING; GENETIC SCREENING; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SERIAL ANALYSIS OF GENE EXPRESSION;

AZACITIDINE; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; RNA, SMALL INTERFERING;

EID: 84857223011     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0109     Document Type: Article

References (30)

1. CBTRUS. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. Chicago: Central Brain Tumor Registry of the United States; 2010.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
4. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005;65:4051-8. (Pubitemid 40775641)
5. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-9.
6. Kanu O, B Hughes, Di C, Lin N, Fu J, Bigner D, et al. Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 2009;3:39-52.
7. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53. (Pubitemid 47339290)
8. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 2007;82:133-9. (Pubitemid 46431855)
9. Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol 2004;165:1151-61. (Pubitemid 39297722)
10. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, et al. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007;28:1264-8. (Pubitemid 47062686)
11. Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2007;26:583-93. (Pubitemid 46160971)
12. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, Tribolet Nd, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
13. Bharti S, Handrow-Metzmacher H, Zickenheiner S, Zeitvogel A, Baumann R, Starzinski-Powitz A. Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells. Mol Biol Cell 2004;15:397-406. (Pubitemid 38044972)
14. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, et al. Digital karyotyping. Proc Natl Acad Sci U S A 2002;99:16156-61. (Pubitemid 35462765)
15. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
16. Parrett TJ, Yan H. Digital karyotyping technology: exploring the cancer genome. Expert Rev Mol Diagn 2005;5:917-25. (Pubitemid 41666186)
17. Jakob V, Schreiner A, Tikkanen R, Starzinski-Powitz A. Targeting of transmembrane protein shrew-1 to adherens junctions is controlled by cytoplasmic sorting motifs. Mol Biol Cell 2006;17:3397-408. (Pubitemid 44156435)
18. Benjelloun A, Delavelle J, Lazeyras F, Dietrich PY. Possible efficacy of temozolomide in a patient with gliomatosis cerebri. Neurology 2001;57:1932-3. (Pubitemid 33096719)
19. McDonald JM, Dunlap S, Cogdell D, Dunmire V, Wei Q, Starzinski- Powitz A, et al. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther 2006;5:300-4.
20. Momparler RL. Preclinical and clinical studies on 5-aza-20-deoxycytidine, a potent inhibitor of DNA methylation, in cancer therapy. In: Szyf M, editor. DNA methylation and cancer therapy: New York: Kluwer Academic/Plenum Publishers; 2005.
21. Dong Z, Pang JS, Ng MH, Poon WS, Zhou L, Ng HK. Identification of two contiguous minimally deleted regions on chromosome 1p36.31- p36.32 in oligodendroglial tumours. Br J Cancer 2004;91:1105-11. (Pubitemid 39336249)
22. Brat DJ, Seiferheld WF, Perry A,Hammond EH, Murray KJ, Schulsinger AR, et al. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro Oncol 2004;6:96-103. (Pubitemid 38455755)
23. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005;24: 2684-94. (Pubitemid 40593096)
24. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008;100:940-9. (Pubitemid 351957513)
25. Milde T, Pfister S, Korshunov A, Deubzer HE, Oehme I, Ernst A, et al. Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes Cancer 2009;48:229-38.
26. Schreiner A, Ruonala M, Jakob V, Suthaus J, Boles E, Wouters F, et al. Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. Mol Biol Cell 2007;18: 1272-81. (Pubitemid 46626622)
27. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23: 2411-22. (Pubitemid 46218735)
28. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation- mediated silencing in malignant glioma. Cancer Res 2006;66: 7490-501. (Pubitemid 44289203)
29. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-20-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8: 358-68. (Pubitemid 27204954)
30. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36. (Pubitemid 46594118)